FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL								
OMB Number: 3235-0104								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Arnold Charlotte C.			2. Date of Event Requiring Statement (Month/Day/Year) 06/19/2013 3. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [BPAX]									
(Last) C/O BIOSAN INC.	C/O BIOSANTE PHARMACEUTICALS,				4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			er	5. If Amendment, Date of Original Filed (Month/Day/Year)			
210 MAIN ST	REET W.				X	Officer (give title below) VP & Chief Financia	Other (spe below) al Officer	ecity	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
(Street) BAUDETTE	MN	56623							71	•	y More than One	
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
		Т	able I - Non	-Derivati	ve Se	curities Beneficial	y Owned					
1. Title of Securi	ty (Instr. 4)	Т	able I - Non	2.	Amou	ecurities Beneficial nt of Securities ally Owned (Instr. 4)	3. Ownersh Form: Dire or Indirect (Instr. 5)	cṫ (D) (I. Natu Instr. 5		Beneficial Ownership	
1. Title of Securi	ty (Instr. 4)		Table II - D	2. Be	Amour eneficia	nt of Securities	3. Ownersh Form: Dire or Indirect (Instr. 5)	ct (D) ((I)			Beneficial Ownership	
Title of Securi Title of Deriva	,	(e.ç	Table II - D	erivative S, warrar	Secunts, o	nt of Securities ally Owned (Instr. 4) urities Beneficially	3. Ownersh Form: Dire or Indirect (Instr. 5) Owned securitie	ct (D) ((I)	sion		Beneficial Ownership 6. Nature of Indirect Beneficial Ownership (Instr. 5)	

Explanation of Responses:

No securities are beneficially owned.

/s/ Roland S. Chase, as attorney-in-fact

06/21/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT

Know all by these presents, that the undersigned hereby constitutes and appoints each of Arthur S. Przybyl, Charlotte C. Arnold, Paul A. Gajer, Jane A. Meyer and Roland S. Chase (the "Authorized Signatories"), or any one or more of them, the undersigned's true and lawful attorneys-in-fact to:

- (1) prepare and execute the attached Form ID;
- (2) prepare and execute for and on behalf of the undersigned, in the undersigned's capacity as an officer or director of BioSante Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder, and any other forms or reports the undersigned may be required to file with the U.S. Securities and Exchange Commission in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4, or 5, or other form or report, and timely file such form or report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of June, 2013.

/s/ Charlotte Arnold
Name: Charlotte Arnold